Relaxin family peptide (RXFPs) 1-4 receptors modulate the activity of cyclic adenosine monophosphate (cAMP) to produce a range of physiological functions. RXFP1 and RXFP2 increase cAMP via Gα s , whereas RXFP3 and RXFP4 inhibit cAMP via Gα i/o . RXFP1 also shows a delayed increase in cAMP downstream of Gα i3 . In this study we have assessed whether the bioluminescence resonance energy transfer (BRET)-based biosensor CAMYEL (cAMP sensor using YFP-Epac-Rluc), which allows real-time measurement of cAMP activity in live cells, will aid in understanding ligand-and cell-specific RXFP signaling. CAMYEL detected concentration-dependent changes in cAMP activity at RXFP1-4 in recombinant cell lines, using a variety of ligands with potencies comparable to those seen in conventional cAMP assays. We used RXFP2 and RXFP3 antagonists to demonstrate that CAMYEL detects dynamic changes in cAMP by reversing cAMP activation or inhibition respectively, with realtime addition of antagonist after agonist stimulation. To demonstrate the utility of CAMYEL to detect cAMP activation in native cells expressing low levels of RXFP receptor, we cloned CAMYEL into a lentiviral vector and transduced THP-1 cells, which express low levels of RXFP1. THP-1 CAMYEL cells demonstrated robust cAMP activation in response to relaxin. However, the CAMYEL assay was unable to detect the Gα i3 -mediated phase of RXFP1 cAMP activation in PTX-treated THP-1 cells or HEK293A cells with knockout of Gα s . Our data demonstrate that cytoplasmically-expressed CAMYEL efficiently detects real-time cAMP activation by Gα s or inhibition by Gα i/o but may not detect cAMP generated in specific intracellular compartments such as that generated by Gα i3 upon RXFP1 activation.
| INTRODUCTION
G protein-coupled receptors (GPCRs) are one of the largest families of proteins in the human genome, and regulate most aspects of human physiology. GPCRs initiate a variety of intracellular signaling cascades in response to a diverse range of ligands, by coupling to effectors including G proteins and β-arrestins. Biased signaling is a key research topic in GPCR drug development, referring to the ability of different ligands to favor coupling of the receptor to particular effectors, leading to activation of only a subset of the receptor's signaling pathways. 1 A related concept is system bias, whereby different cell types can show preferential coupling to particular downstream signaling pathways. 2 The relaxin family of peptides target GPCRs to produce a broad array of physiological functions across a range of tissues including the reproductive system, cardiovascular system, connective tissue, gastrointestinal tract, and brain (reviewed in [3, 4] are the cognate ligands for RXFP1 6 and RXFP2, 7 and relaxin-3 and INSL5 are the cognate ligands for RXFP3 8 and RXFP4, 9 respectively.
The receptors for INSL4 and INSL6 have not been identified.
One of the primary second messengers involved in RXFP receptor signaling is 3′,5′-cyclic adenosine monophosphate (cAMP). Effectors of cAMP include protein kinase A (PKA), exchange protein directly activated by cAMP (Epac), and cyclic nucleotide-gated ion channels. Activation of a Gα s -coupled GPCR leads to synthesis of cAMP via adenylate cyclases (ACs), whereas activation of a Gα i/ocoupled receptor leads to inhibition of ACs. RXFP1 and RXFP2 couple to Gα s to increase cAMP activity, which is negatively modulated by Gα oB . 6, 10 Unusually, RXFP1 also couples to Gα i3 to increase cAMP downstream of Gβγ, PI3K, PKC-ζ, and AC5 in a number of cell types. [10] [11] [12] [13] In contrast, RXFP3 and RXFP4 couple to Gα i/o proteins to inhibit the production of cAMP. 14, 15 However, patterns of cAMP activity also depend on the cell type being stimulated. For example, fibroblasts that natively express RXFP1 show little or no increases in cAMP activity when stimulated with an RXFP1 agonist. [16] [17] [18] Traditional assays for detecting cAMP activity do not easily measure the temporal aspects of signaling, but measuring the kinetics of signaling aids accurate detection of biased signaling. 19 A real-time assay for cAMP activity that can be used in native cells will therefore be valuable for understanding ligand-and cell-specific effects of RXFP signaling, as well as for screening novel ligands acting at these receptors. Fortunately, there is a real-time, genetically-encoded bioluminescence resonance energy transfer (BRET)-based biosensor for cAMP activity. BRET is the transfer of energy from an excited luciferase donor to a fluorophore acceptor, when they are in close proximity. CAMYEL (cAMP sensor using YFP-Epac-Rluc) is a unimolecular BRET-based biosensor for cAMP activity, consisting of truncated and catalytically inactive human Epac1 sandwiched between Rluc (the donor) and a monomeric and circularly permuted form of the YFP citrine (the acceptor). 20 When cAMP is not present, Epac adopts a "closed" conformation, where the donor and acceptor are in close proximity, producing a BRET signal. When cAMP binds to Epac, the donor and acceptor move farther apart, reducing BRET. These changes in BRET can be monitored in real time in live cells at 37°C.
In this study, we demonstrated the use and versatility of CAMYEL for detecting real-time cAMP activity at RXFP1-4 and developed and validated a CAMYEL lentiviral vector for the transduction of native cells expressing RXFP1. However, we were unable to detect the delayed phase of cAMP activity at RXFP1 mediated by Gα i3 suggesting that the CAMYEL sensor, when expressed in the cytoplasm, may not detect cAMP generated in specific intracellular compartments. 
| MATERIALS AND METHODS

| Reagents and materials
| Synthesis of H2 relaxin labeled with TAMRA
Individual A-and B-chains of H2 relaxin with appropriate regioselective S-protection were synthesised using a CEM Liberty peptide synthesiser. 27 The amine-reactive fluorophore 5(6)-TAMRA succinimidyl ester (Anaspec) was attached to the N-terminus of the A-chain sequence using a manual coupling procedure. Following purification of the crude peptides stepwise formation of the three disulfide bonds was conducted as described. 27 The final TAMRA-labelled H2
relaxin was subjected to characterization by RP-HPLC and MALDI-TOF mass spectrometry to confirm its high purity and correct molec- 
| Cell culture
Cell culture media was supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, and 1% L-glutamine (complete media).
Human embryonic kidney (HEK) 293T and 293A cells were grown in 
| Production of the THP-1 CAMYEL stable cell lines
For transduction of THP-1 suspension cells with CAMYEL lentivirus, a spinoculation protocol using purified lentivirus was followed. 
| RESULTS
| Detection of cAMP activity at RXFP1
To establish the range of intracellular cAMP activity that can be detected using CAMYEL HEK-RXFP1 cells transiently transfected with CAMYEL were stimulated with a range of concentrations of forskolin, a diterpene that directly activates adenylate cyclase. 33 HEK-RXFP1 cells showed fast, concentration-dependent increases in cAMP activity that peaked at about 5-10 minutes and were sustained over 45 minutes ( Figure 1A) . A concentration-response curve generated for 45 minutes showed a potency (pEC 50 ) of 6.77 ± 0.07 ( Figure 1B ) and a maximal response at 10 μmol L −1 forskolin.
After establishing that CAMYEL can detect concentration-dependent increases in cAMP activity in HEK-RXFP1 cells, we investigated showed slow decreases in cAMP activity after peaking at about 5 minutes. Concentration-response curves were generated for five and 45 minutes to compare ligand efficacy and potency values over time ( Figure 1E , Table 1 ). Ligand efficacy was greater at 45 minutes compared to 5 minutes and was similar for both ligands. However, the potency of H2 relaxin was >10 000 times higher than that of ML290 at both time points (P < 0.01).
| Detection of cAMP activity at RXFP2
A Table 2 ).
As stimulation of HEK-RXFP1 and HEK-RXFP2 both demonstrate rapid and sustained increases in cAMP, it is possible that the CAMYEL sensor is not dynamic and does not easily reverse the conformational change that occurs when cAMP binds. To simply assess whether the sensor was able to respond to rapid changes in cAMP we utilized a specific receptor antagonist. As there is no relevant RXFP1 antagonist we utilized a well-characterized RXFP2 antagonist INSL3 B-chain dimer. 22 Blockade of RXFP2 by the antagonist 10 minutes before adding the agonist INSL3 abolished the ability of INSL3 to increase cAMP activity ( Figure 2F ). Importantly, addition of antagonist 10 minutes after addition of INSL3 resulted in real-time reversal of the BRET signal highlighting the CAMYEL sensor is able to respond to dynamic changes in cAMP activity.
| Inhibition of cAMP activity at RXFP3
We Table 3 ). Notably, ligand efficacy was not different at 10 or 45 minutes however, peptide 5 demonstrated greater potency at 45 minutes than at 10 minutes and was more potent than analogue 2 only at 45 minutes (P < 0.05).
As our lab also had HEK-RXFP3 cells, they were also tested for agonist-induced cAMP inhibition together with another agonist, R3/ I5. Forskolin is more potent in HEK293T than CHO-K1 cells, so we ). Data represent mean ± SEM of three independent experiments. *P < 0.01 compared to 5 minutes; **P < 0.05 compared to 5 minutes; ***P < 0.01 compared to H2 relaxin (unpaired t-tests). Figure 4B ), again demonstrating that we are able to measure dynamic cAMP changes using the CAMYEL sensor.
| Inhibition of cAMP activity at RXFP4
Finally, in our initial characterisation of CAMYEL in recombinant cells, we tested the ability of agonists to inhibit cAMP activity at RXFP4. We only had CHO-K1 cells stably expressing RXFP4
(CHO-RXFP4) available, and tested the native ligand INSL5 and analogue 13. 26 As with CHO-RXFP3, cells were pre-incubated for 4 minutes with agonist, before adding forskolin at a concentration of 10 μmol L −1 , which is the approximate EC 50 for forskolin in these cells ( Figure S3 ). The two agonists showed concentrationdependent decreases in cAMP activity, which plateaued after about 30 minutes ( Figure 5A and B). Concentration-response curves were generated for 10 and 45 minutes, expressed as a ). Data represent mean ± SEM of three independent experiments. *P < 0.01 compared to 5 minutes; **P < 0.01 compared to INSL3 (unpaired t-tests).
percentage of forskolin activity at the same time point ( Figure 5C ).
At 45 minutes, the efficacy of INSL5 was greater than that of analogue 13 but this was not statistically significant (P > 0.05) ( Table 5 ). The lower efficacy of the ligands seen in these cells Human monocytic leukaemia THP-1 cells have commonly been used for detecting relaxin induced cAMP activity even though they have low endogenous expression of RXFP1 (~275 receptors per cell 35 ), in contrast to HEK-RXFP1 cells, which have~50 000-100 000 receptors per cell. 36 As THP-1 cells are a non-adherent cell line we used a spinoculation protocol involving purified lentivirus to transduce the cells, followed by sorting using FACS into populations expressing low, medium, or high levels of CAMYEL ( Figure 6 ). The "high" CAMYEL population was initially tested for concentrationdependent increases in forskolin-induced cAMP activity ( Figure 7A ).
Forskolin produced rapid dose-dependent increases in cAMP with a maximum response at 100 μmol L −1 and a higher potency at 5 minutes (5.29 ± 0.03) than at 45 minutes (4.93 ± 0.05) (P < 0.01) (Figure 7B) . ). Data represent mean ± SEM of three independent experiments. *P < 0.05 compared to analogue 2 (unpaired t-test). ). Data represent mean ± SEM of three independent experiments. Figure 7D, F, H) . Notably, there was no difference in H2 relaxin efficacy or potency between the cells, indicating the level of CAMYEL had no effect on the response to H2 relaxin (Table 6 ). Ligand efficacy was greater at 5 minutes as expected from the shape of the response curves, but ligand potency was higher at 45 minutes (P < 0.05).
T A B L E 4 Efficacy and potency of agonists acting at RXFP3 in HEK293T cells
Relaxin-stimulated intracellular cAMP accumulation through RXFP1 has been shown to be modulated by three G proteins. Immediate increases in cAMP are mediated by Gα s and negatively modulated by Gα oB , 10 whereas there is a delayed increase in cAMP activity after~15 minutes mediated by Gα i3 in a number of cell types, including HEK-RXFP1 and THP-1. 10, 12, 13 However, using the CAMYEL assay we have not detected a biphasic increase in cAMP activity at RXFP1. To investigate further, we tested the effect of treatment with PTX (100 ng mL suggesting we are not seeing a delayed Gα i3 -mediated enhancement of cAMP.
3.7 | Dissecting RXFP1 cAMP activity using
HEK293A ΔGα s cells
To further investigate this potential lack of Gα i3 cAMP effect we used novel HEK293A cells with CRISPR/Cas9-mediated knockout of Gα s members (GNAS and GNAL genes). 30 We first produced forskolin concentration-response data for the HEK293A parental and Gα s knockout (ΔGα s ) cells. HEK293A parental cells showed robust increases in cAMP activity that were very similar to those seen earlier in HEK293T cells expressing RXFP1 or RXFP2 ( Figure 9A ). However, the ΔGα s cells showed very weak cAMP activity, requiring relatively high concentrations of forskolin (>10 μmol L −1 ) to detect a cAMP increase, which was only transient ( Figure 9B) . As forskolin has a lower affinity for adenylate cyclase in the absence of Gα s , 37 we transfected Gα s into these cells to show that forskolin potency could be rescued by re-expression of Gα s ( Figure 9C ). At 45 minutes, the potency of forskolin in HEK293A parental cells was 5.91 ± 0.04.
In ΔGα s cells with re-expression of Gα s , the potency was 7.1 ± 1.29
( Figure 9D ).
T A B L E 6
Efficacy and potency of H2 relaxin in the THP-1 CAMYEL stable cell line ), which targets Gα s -coupled β-adrenoceptors endogenous to HEK293 cells, was used as a control for these experiments to confirm lack of Gα s activity. As expected, the response to isoprenaline was robust in the parental cells ( Figure 9E ), but was abolished in the ΔGα s cells ( Figure 9F) .
Similarly, the response to H2 relaxin (100 pmol L −1 -100 nmol L Agonists at the four receptors also showed similar potencies to those already seen using traditional cAMP end point assays.
The sustained cAMP activity seen at RXFP1 and RXFP2 is consistent with the finding that these receptors lack β-arrestin-mediated desensitization and show poor internalization in response to ligand stimulation. 39 However, we also saw sustained cAMP inhibition at RXFP3
(particularly in HEK293T cells) and RXFP4, which have been shown to interact with β-arrestins and internalize after stimulation with their endogenous ligands. 14, 15 Although the original characterization of CAMYEL in RAW 264.7 murine macrophage cells showed that CAMYEL can report substantial and rapid decreases in BRET signal, 20 studies on some GPCRs, including the cannabinoid 1, 40 dopamine D 2 L, 19 and muopioid 34 receptors, have also shown relatively sustained changes in CAMYEL signal over extended periods of time. However, most studies using CAMYEL do not show time-course data and some include phosphodiesterase inhibitors in the assay to stop the breakdown of cAMP.
As sustained changes in the BRET signal have been observed in the present study and other studies, it was thought possible that cAMP does not easily dissociate from the sensor, or that the sensor does not easily reverse its conformation and therefore does not precisely detect realtime fluctuations in cAMP levels. Therefore, we demonstrated reversibility of the BRET signal at RXFP2 and RXFP3 by adding an antagonist after pre-incubation with agonist, which both showed real-time reversal of the signal. These experiments demonstrated that the sensor is dynamic and able to detect changes in BRET signal reflective of changes in cAMP levels, over extended periods of time.
Targeting RXFP receptors with drugs has potential for a range of therapeutic applications (reviewed in 4). Much effort has therefore been put into designing analogues of relaxin family peptides, including agonists and antagonists used in the present study. 41 In particular, RXFP1 is a promising therapeutic target for cardiovascular diseases and fibrosis.
Novel ligands acting at RXFP1, including peptide analogues (e.g., 42 ) and small molecules, 21 have been screened in THP-1 cells due to the robust cAMP activation by relaxin in these cells. Our newly-developed THP-1 CAMYEL cell line will be a valuable tool for drug discovery targeting RXFP1, as it is sensitive and able to detect concentration-dependent increases in cAMP activity over time in the absence of phosphodiesterase inhibitors. Importantly, the assay showed a similar potency of H2 relaxin to that observed using traditional cAMP assays such as enzyme immunoassay 43 and HTRF cAMP assays. 42 The THP-1 CAMYEL assay also streamlines the process of screening ligands, as these suspen- RXFP1 has been shown to couple to at least three G proteins to modulate cAMP activity in some human cells. Gα s is the primary mediator of cAMP, and its actions are negatively modulated by Gα oB. 10 Further increases in cAMP activity have also been shown to occur in a number of cell types, including THP-1, 13 HEK-RXFP1, 10 and some human primary vascular cell types 44 downstream of Gα i3 , Gβγ, PI3K, PKCζ, and adenylate cyclase 5. 10, 12, 13 Coupling of RXFP1 to Gα i3 has also been confirmed by BRET protein-protein interaction studies, 16 and is dependent on localization of RXFP1 and Gα i/o in membrane raft microdomains. 45 This finding suggests that cAMP activity at RXFP1 is VALKOVIC ET AL.
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compartmentalized, which is consistent with the finding that in HEK-RXFP1 cells, Gα s -induced cAMP activity affects CRE transcription, whereas Gα i3 -induced cAMP activity affects NFκB transcription. 46 In the present study, PTX inhibition in THP-1 CAMYEL cells demonstrated a potential inhibition by Gα oB at 5 minutes which was not significant but no effect at any other time point indicated a complete absence of a Gα i3 effect. We then used HEK293A cells that do not express the Gα s subunit to further investigate. Although the potency of forskolin was diminished in these cells, re-expression of Gα s restored the potency of forskolin, showing that the diminished forskolin response was not an off-target effect of the gene editing in these cells. However, stimulation of these cells with H2 relaxin when RXFP1 and CAMYEL were coexpressed did not show any increases in cAMP activity, including when adenylate cyclase was primed using forskolin to compensate for the loss of Gα s . Therefore, we have been unable to reproduce the Gα i3 -mediated increase in cAMP activity at RXFP1 using the CAMYEL assay. It is therefore possible that there is a localized pool of cAMP that CAMYEL is unable to detect. The original paper that described CAMYEL 20 suggested that CAMYEL is expressed throughout the cytoplasm, as it uses a cytosolic mutant of Epac1. 47 Further studies have shown cytosolic distribution of CAMYEL via confocal microscopy and western blot. 48 We have confirmed this using confocal microscopy in HEK293T cells stably expressing CAMYEL (data not shown). Importantly, there is precedent for the inability of cytosolic biosensors to detect localized hotspots of cAMP activity. For example, in GH 3 B 6 cells treated with vasoactive intestinal peptide, FRET-based biosensors for cAMP activity located around the cytosol or localized to the plasma membrane reported robust cAMP increases that were not detected by an AC8-localized sensor. 49 In contrast, increases in cAMP activity after stimulation with thyrotropinreleasing hormone were detected by the AC8-localized sensor but not the cytosolic or membrane forms. 49 In summary, CAMYEL is a valuable tool for the direct detection of real-time cAMP activity at the relaxin family peptide receptors 1-4. We have shown robust cAMP activation and inhibition at Gα s -and Gα i/ocoupled receptors when CAMYEL was transfected into recombinant cell lines, and have also shown robust cAMP activity in a cell line that expresses low native levels of RXFP1, when CAMYEL was delivered virally. We have also detected differences in cAMP activity between different ligands and cell types, which can be modulated by antagonists and an inhibitor. However, we could not replicate the biphasic cAMP response at RXFP1 using this assay, which may suggest compartmentalization of cAMP activity at RXFP1, consistent with previous findings. The development of a lentiviral CAMYEL construct will allow the transduction of any mammalian cell for the real-time analysis of cAMP signaling.
